Volition Veterinary Diagnostics Development LLC Announces Product Data Regarding its Nu.Q™ Vet Cancer Screening Test in Lymphoma and Hemangiosarcoma to be Presented at the 2020 VCS Virtual Annual Conference
- Positive data show high sensitivity and specificity in the detection of Lymphoma and Hemangiosarcoma as Volition remains on target for launch of its first product expected later this year
- Cancer is the most common cause of death in dogs over the age of two years old in the U.S.
- Together, Lymphoma and Hemangiosarcoma make up approximately one-third of canine cancers
AUSTIN, Texas, Oct. 16, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, is presenting two abstracts with new data on its first product, the Nu.Q™ Vet Cancer Screening Test, at the 2020 Veterinary Cancer Society (VCS) Virtual Annual Conference, which takes place from Thursday, October 15 through Saturday, October 17.
"The data demonstrate that the Nu.Q™ Vet Cancer Screening Test has a high sensitivity and specificity in relation to both Lymphoma and Hemangiosarcoma detection in a large and varied cohort," said Heather Wilson-Robles, Professor at Texas A&M University, Chief Medical Officer of Volition Veterinary Diagnostics Development LLC, and President-Elect of the VCS. "The results show an Area Under the Curve (AUC) of 87.3% and 97.6%, respectively, for Lymphoma and Hemangiosarcoma.
Dr. Robles added, "These positive findings provide us with real confidence as we move forward towards the launch of our first product, the Nu.Q™ Vet Cancer Screening Test, anticipated in the coming weeks. Early diagnosis has a huge potential to help improve the treatment and the quality of life for dogs as well as providing valuable additional information to inform the clinical decision-making process."
An interview with Heather Wilson-Robles, Chief Medical Officer of Volition Veterinary Diagnostics Development LLC.
Cancer is the most common cause of death in dogs over the age of two years old in the U.S. and up to 50% of all dogs over the age of 10 develop cancer in their lifetime. Together, Lymphoma and Hemangiosarcoma make up approximately one third of canine cancers. Currently, dogs suspected of having cancer are required to undergo a variety of diagnostic tests that may be expensive, time consuming and/or painful for the animal. The Nu.Q™ Vet Cancer Screening Test is a low-cost, easy to use ELISA-based screening test that measures and identifies circulating nucleosomes, which are early markers of cancer, from a simple blood sample to enable a streamlined and less invasive diagnostic process.
The studies were carried out at Texas A&M University on 334 samples (Healthy Control n=134, Lymphoma n=127, Hemangiosarcoma n=73) which included a variety of breeds, genders, weights, ages and different cancer stages.
Characterizing Circulating Nucleosomes in the Plasma of Dogs with Lymphoma
Friday, October 16 at 1:30 p.m. Eastern Time
Characterizing Circulating Nucleosomes in the Plasma of Dogs with Hemangiosarcoma
Saturday, October 17 at 11:15 a.m. Eastern Time
To register for the 2020 Virtual Veterinary Cancer Society Annual Conference please click here.
The abstracts will be posted to the Volition website on Monday October 19.
To learn more about Volition Veterinary and Nu.Q™ Vet please visit our new webpage at https://volition.com/veterinary and/or register for Volition's Capital Markets Day presentation on Tuesday, October 20 at 8:00 a.m. Eastern Time here.
Volition is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of NucleosomicsTM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.
Volition's research and development activities are centered in Belgium, with additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.
NucleosomicsTM and Nu.Q™ and their respective logos are trademarks of Volition and its subsidiaries.
For more information about Volition, visit Volition's website (http://www.volition.com) or connect with us via:
The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.
Media / Investor Contacts
Louise Batchelor, Volition
+44 (0)7557 774620
Scott Powell, Volition
+1 (646) 650 1351
Jen Lewis, Pegasus
+44 (0)7809 867943
Joseph Green, Edison Advisors
+1 (646) 653 7030
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the timing of the commercial launch of Volition's test platforms for early detection of cancer and other diseases. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic or prognostic products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic or prognostic products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; downturns in domestic and foreign economies; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
View original content to download multimedia:http://www.prnewswire.com/news-releases/volition-veterinary-diagnostics-development-llc-announces-product-data-regarding-its-nuq-vet-cancer-screening-test-in-lymphoma-and-hemangiosarcoma-to-be-presented-at-the-2020-vcs-virtual-annual-conference-301153913.html
SOURCE VolitionRx Ltd
Released October 16, 2020